Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC-DLBP phase II trial in discogenic low back pain
ChiCTR2200058291Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
- Start
- May 2022
- Modality
- Stem Cell Therapies → Cell Therapies, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of autologous adipose-derived mesenchymal stromal cells and Tissuefill in discogenic back pain (4 arms), sponsored by The First Affiliated Hospital of Dalian Medical University. Primary endpoint: Visual analogue scale. Planned start May 2022; status: not yet recruiting.
02
Drugs
autologous adipose-derived mesenchymal stromal cellsTissuefill
03
Conditions
discogenic back pain
Beyond the preview
Go deeper on ChiCTR2200058291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058291.